Clinical Trial Update: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease [Phase 3]

View source ↗

Summary

An update on a Phase 3 trial of Simufilam at 50 mg or 100 mg for Alzheimer's disease shows the study was terminated and results were posted on 2025-09-22. Addit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Simufilam (simufilam)

Snippet

Sponsor: Cassava Sciences, Inc. | Conditions: Alzheimer Disease | Phase 3 | Status: TERMINATED | Results posted: 2025-09-22